Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 235 | 2024 | 1952 | 28.810 |
Why?
|
Heart-Assist Devices | 62 | 2023 | 485 | 13.380 |
Why?
|
Atrial Fibrillation | 37 | 2022 | 324 | 5.160 |
Why?
|
Decision Making | 25 | 2023 | 781 | 4.800 |
Why?
|
Patient Readmission | 27 | 2023 | 608 | 4.500 |
Why?
|
Stroke Volume | 43 | 2023 | 508 | 4.170 |
Why?
|
Decision Support Techniques | 16 | 2022 | 351 | 3.880 |
Why?
|
Ventricular Dysfunction, Left | 15 | 2023 | 359 | 3.350 |
Why?
|
Registries | 47 | 2023 | 1759 | 3.150 |
Why?
|
Quality of Life | 42 | 2023 | 2358 | 2.920 |
Why?
|
Heart Transplantation | 16 | 2023 | 667 | 2.830 |
Why?
|
Cardiology | 18 | 2022 | 259 | 2.660 |
Why?
|
Humans | 322 | 2024 | 114757 | 2.650 |
Why?
|
Patient Participation | 15 | 2023 | 360 | 2.620 |
Why?
|
Aged | 135 | 2024 | 19094 | 2.340 |
Why?
|
Palliative Care | 19 | 2023 | 641 | 2.280 |
Why?
|
Hospice Care | 9 | 2021 | 185 | 2.250 |
Why?
|
Caregivers | 16 | 2023 | 717 | 2.250 |
Why?
|
Guideline Adherence | 11 | 2021 | 490 | 2.230 |
Why?
|
Defibrillators, Implantable | 15 | 2022 | 286 | 2.200 |
Why?
|
Patient Discharge | 27 | 2023 | 769 | 2.100 |
Why?
|
Ventricular Function, Left | 17 | 2023 | 467 | 2.020 |
Why?
|
Hospitalization | 41 | 2023 | 1752 | 2.010 |
Why?
|
United States | 104 | 2024 | 12176 | 2.010 |
Why?
|
Practice Patterns, Physicians' | 11 | 2020 | 1178 | 1.940 |
Why?
|
Medicare | 31 | 2024 | 665 | 1.920 |
Why?
|
Terminal Care | 9 | 2020 | 213 | 1.880 |
Why?
|
Male | 155 | 2024 | 55579 | 1.760 |
Why?
|
Middle Aged | 106 | 2023 | 26757 | 1.760 |
Why?
|
Female | 160 | 2024 | 59507 | 1.720 |
Why?
|
Cardiotonic Agents | 10 | 2021 | 119 | 1.700 |
Why?
|
Risk Assessment | 32 | 2023 | 2973 | 1.680 |
Why?
|
Outpatients | 10 | 2023 | 327 | 1.680 |
Why?
|
Aged, 80 and over | 62 | 2023 | 6350 | 1.660 |
Why?
|
Patient Preference | 6 | 2018 | 167 | 1.620 |
Why?
|
Ambulatory Care | 7 | 2019 | 479 | 1.600 |
Why?
|
Myocardial Infarction | 9 | 2023 | 927 | 1.490 |
Why?
|
Health Status | 14 | 2023 | 723 | 1.490 |
Why?
|
American Heart Association | 17 | 2023 | 264 | 1.420 |
Why?
|
Patient-Centered Care | 12 | 2024 | 474 | 1.390 |
Why?
|
Anticoagulants | 17 | 2022 | 547 | 1.390 |
Why?
|
Treatment Outcome | 54 | 2023 | 9089 | 1.390 |
Why?
|
Withholding Treatment | 5 | 2019 | 68 | 1.320 |
Why?
|
Delivery of Health Care | 11 | 2023 | 833 | 1.310 |
Why?
|
Prognosis | 29 | 2023 | 3334 | 1.310 |
Why?
|
Inpatients | 5 | 2023 | 378 | 1.300 |
Why?
|
Heart Ventricles | 6 | 2021 | 709 | 1.300 |
Why?
|
Aminobutyrates | 7 | 2023 | 32 | 1.260 |
Why?
|
Family | 4 | 2023 | 591 | 1.260 |
Why?
|
Aftercare | 17 | 2023 | 186 | 1.240 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2021 | 1214 | 1.230 |
Why?
|
Hospitals | 10 | 2024 | 580 | 1.200 |
Why?
|
Practice Guidelines as Topic | 12 | 2019 | 1393 | 1.190 |
Why?
|
Health Expenditures | 5 | 2023 | 171 | 1.170 |
Why?
|
Angiotensin Receptor Antagonists | 10 | 2023 | 76 | 1.170 |
Why?
|
Stroke | 15 | 2022 | 1019 | 1.160 |
Why?
|
Cardiovascular Agents | 3 | 2018 | 125 | 1.150 |
Why?
|
Risk Factors | 46 | 2023 | 8627 | 1.110 |
Why?
|
Valsartan | 6 | 2022 | 22 | 1.100 |
Why?
|
Biphenyl Compounds | 7 | 2022 | 50 | 1.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 8 | 2023 | 179 | 1.090 |
Why?
|
Patient Care Management | 3 | 2017 | 53 | 1.090 |
Why?
|
Cardiovascular Diseases | 14 | 2022 | 1727 | 1.070 |
Why?
|
Surveys and Questionnaires | 21 | 2023 | 4625 | 1.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 9 | 2021 | 1183 | 1.040 |
Why?
|
Consumer Health Information | 3 | 2017 | 47 | 1.040 |
Why?
|
Drug Costs | 4 | 2020 | 91 | 1.020 |
Why?
|
Adrenergic beta-Antagonists | 7 | 2019 | 287 | 0.990 |
Why?
|
Heart Failure, Systolic | 3 | 2018 | 20 | 0.980 |
Why?
|
Patient Selection | 10 | 2019 | 641 | 0.970 |
Why?
|
Acute Coronary Syndrome | 2 | 2023 | 254 | 0.960 |
Why?
|
Biomedical Research | 3 | 2020 | 585 | 0.950 |
Why?
|
Death, Sudden, Cardiac | 4 | 2021 | 160 | 0.950 |
Why?
|
Internet | 4 | 2020 | 596 | 0.940 |
Why?
|
Anti-Arrhythmia Agents | 4 | 2020 | 106 | 0.920 |
Why?
|
Quality Improvement | 6 | 2021 | 951 | 0.920 |
Why?
|
Health Care Costs | 7 | 2023 | 380 | 0.910 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 2 | 2020 | 29 | 0.900 |
Why?
|
Patient Education as Topic | 4 | 2018 | 679 | 0.900 |
Why?
|
Survival Analysis | 14 | 2019 | 1218 | 0.890 |
Why?
|
Cardiovascular System | 5 | 2022 | 125 | 0.880 |
Why?
|
Quality of Health Care | 8 | 2024 | 573 | 0.880 |
Why?
|
Follow-Up Studies | 25 | 2023 | 4420 | 0.870 |
Why?
|
Patient Reported Outcome Measures | 10 | 2023 | 250 | 0.870 |
Why?
|
Cannabis | 2 | 2022 | 384 | 0.870 |
Why?
|
Protease Inhibitors | 2 | 2020 | 97 | 0.860 |
Why?
|
Physicians | 7 | 2023 | 772 | 0.850 |
Why?
|
Heart Injuries | 1 | 2023 | 36 | 0.830 |
Why?
|
Clinical Decision-Making | 7 | 2023 | 268 | 0.820 |
Why?
|
Spirituality | 1 | 2023 | 69 | 0.810 |
Why?
|
Diuretics | 4 | 2023 | 66 | 0.780 |
Why?
|
Informed Consent | 3 | 2023 | 161 | 0.770 |
Why?
|
Device Removal | 2 | 2020 | 126 | 0.760 |
Why?
|
Catheter Ablation | 4 | 2020 | 291 | 0.750 |
Why?
|
Insurance, Health | 3 | 2017 | 244 | 0.740 |
Why?
|
Percutaneous Coronary Intervention | 2 | 2023 | 444 | 0.740 |
Why?
|
Transitional Care | 3 | 2021 | 34 | 0.720 |
Why?
|
Length of Stay | 7 | 2018 | 949 | 0.720 |
Why?
|
Retrospective Studies | 38 | 2023 | 12515 | 0.710 |
Why?
|
Health Policy | 3 | 2021 | 334 | 0.700 |
Why?
|
Medication Adherence | 6 | 2021 | 537 | 0.700 |
Why?
|
Adult | 48 | 2023 | 30548 | 0.700 |
Why?
|
Population Health | 1 | 2020 | 42 | 0.680 |
Why?
|
Attitude to Death | 4 | 2023 | 62 | 0.670 |
Why?
|
Cardiomyopathies | 3 | 2015 | 298 | 0.670 |
Why?
|
Biomarkers | 7 | 2023 | 3416 | 0.670 |
Why?
|
Cause of Death | 8 | 2020 | 362 | 0.660 |
Why?
|
Telemedicine | 6 | 2024 | 663 | 0.660 |
Why?
|
Patient Rights | 1 | 2019 | 10 | 0.660 |
Why?
|
Mineralocorticoid Receptor Antagonists | 4 | 2018 | 38 | 0.650 |
Why?
|
Drug Substitution | 2 | 2018 | 46 | 0.650 |
Why?
|
Propanolamines | 1 | 2019 | 90 | 0.640 |
Why?
|
Medicaid | 4 | 2021 | 407 | 0.640 |
Why?
|
Hemorrhage | 10 | 2022 | 618 | 0.630 |
Why?
|
Time Factors | 22 | 2023 | 6124 | 0.630 |
Why?
|
Interviews as Topic | 9 | 2021 | 582 | 0.620 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 340 | 0.620 |
Why?
|
Quality Assurance, Health Care | 3 | 2015 | 311 | 0.620 |
Why?
|
Coronavirus Infections | 2 | 2020 | 332 | 0.620 |
Why?
|
Patient Care Team | 4 | 2018 | 517 | 0.610 |
Why?
|
Hospices | 5 | 2021 | 83 | 0.610 |
Why?
|
Health Status Indicators | 3 | 2020 | 156 | 0.600 |
Why?
|
Manuscripts, Medical as Topic | 1 | 2017 | 4 | 0.600 |
Why?
|
Warfarin | 7 | 2022 | 135 | 0.590 |
Why?
|
Heart Diseases | 2 | 2014 | 330 | 0.590 |
Why?
|
Attitude to Health | 4 | 2019 | 406 | 0.580 |
Why?
|
Peer Review | 1 | 2017 | 43 | 0.580 |
Why?
|
Peer Review, Research | 1 | 2017 | 34 | 0.580 |
Why?
|
Physician-Patient Relations | 3 | 2020 | 462 | 0.580 |
Why?
|
Cocaine | 1 | 2019 | 153 | 0.580 |
Why?
|
Stress, Psychological | 3 | 2021 | 944 | 0.570 |
Why?
|
Editorial Policies | 1 | 2017 | 45 | 0.560 |
Why?
|
Disease Progression | 14 | 2019 | 2387 | 0.560 |
Why?
|
Insurance Claim Review | 2 | 2014 | 67 | 0.550 |
Why?
|
Advance Care Planning | 2 | 2019 | 197 | 0.550 |
Why?
|
Heart Valve Prosthesis Implantation | 2 | 2021 | 175 | 0.550 |
Why?
|
Prospective Studies | 20 | 2022 | 6217 | 0.550 |
Why?
|
Angina, Unstable | 3 | 2006 | 72 | 0.540 |
Why?
|
Health Plan Implementation | 1 | 2017 | 132 | 0.540 |
Why?
|
Quality Indicators, Health Care | 7 | 2021 | 287 | 0.530 |
Why?
|
Societies, Medical | 5 | 2019 | 663 | 0.520 |
Why?
|
Comorbidity | 13 | 2023 | 1449 | 0.520 |
Why?
|
Disease Management | 6 | 2022 | 560 | 0.520 |
Why?
|
Clinical Trials as Topic | 6 | 2019 | 935 | 0.520 |
Why?
|
Survival Rate | 10 | 2020 | 1642 | 0.510 |
Why?
|
Aortic Valve Stenosis | 2 | 2021 | 272 | 0.510 |
Why?
|
Digoxin | 1 | 2015 | 26 | 0.500 |
Why?
|
Appointments and Schedules | 1 | 2016 | 73 | 0.500 |
Why?
|
Healthcare Disparities | 7 | 2023 | 479 | 0.500 |
Why?
|
Periodicals as Topic | 1 | 2017 | 181 | 0.500 |
Why?
|
Heart Rate | 4 | 2020 | 704 | 0.500 |
Why?
|
Natriuretic Peptide, Brain | 5 | 2022 | 96 | 0.490 |
Why?
|
Cohort Studies | 16 | 2023 | 4901 | 0.490 |
Why?
|
Activities of Daily Living | 2 | 2016 | 350 | 0.480 |
Why?
|
Multimedia | 1 | 2014 | 10 | 0.480 |
Why?
|
Frail Elderly | 2 | 2013 | 105 | 0.480 |
Why?
|
Drug Prescriptions | 2 | 2018 | 239 | 0.470 |
Why?
|
Health Personnel | 2 | 2022 | 574 | 0.470 |
Why?
|
Proportional Hazards Models | 13 | 2019 | 1080 | 0.470 |
Why?
|
Colorado | 12 | 2021 | 4086 | 0.460 |
Why?
|
Severity of Illness Index | 8 | 2018 | 2539 | 0.460 |
Why?
|
Population Surveillance | 1 | 2017 | 392 | 0.460 |
Why?
|
Socioeconomic Factors | 6 | 2022 | 1078 | 0.450 |
Why?
|
Skilled Nursing Facilities | 2 | 2016 | 121 | 0.450 |
Why?
|
Fluid Therapy | 1 | 2015 | 122 | 0.450 |
Why?
|
Acute Disease | 7 | 2023 | 912 | 0.450 |
Why?
|
Marijuana Abuse | 1 | 2016 | 212 | 0.450 |
Why?
|
Hip Prosthesis | 1 | 2014 | 33 | 0.450 |
Why?
|
Hospital Mortality | 8 | 2023 | 776 | 0.450 |
Why?
|
Shock, Cardiogenic | 1 | 2014 | 53 | 0.440 |
Why?
|
Hyperkalemia | 1 | 2013 | 26 | 0.440 |
Why?
|
Hand Strength | 1 | 2014 | 95 | 0.440 |
Why?
|
Tetrazoles | 6 | 2023 | 32 | 0.430 |
Why?
|
Preoperative Period | 1 | 2013 | 103 | 0.430 |
Why?
|
Life Expectancy | 2 | 2016 | 51 | 0.430 |
Why?
|
Electrocardiography | 5 | 2023 | 562 | 0.430 |
Why?
|
Prosthesis Failure | 1 | 2014 | 117 | 0.420 |
Why?
|
Algorithms | 4 | 2022 | 1468 | 0.420 |
Why?
|
Drug Combinations | 7 | 2022 | 286 | 0.420 |
Why?
|
Models, Statistical | 2 | 2014 | 604 | 0.420 |
Why?
|
Patient Admission | 3 | 2015 | 176 | 0.410 |
Why?
|
Arrhythmias, Cardiac | 4 | 2022 | 278 | 0.410 |
Why?
|
Furosemide | 2 | 2023 | 32 | 0.410 |
Why?
|
Coronary Artery Bypass | 2 | 2011 | 198 | 0.410 |
Why?
|
Neprilysin | 3 | 2023 | 47 | 0.400 |
Why?
|
Cardiac Catheterization | 3 | 2020 | 534 | 0.400 |
Why?
|
Chronic Disease | 10 | 2022 | 1590 | 0.400 |
Why?
|
Qualitative Research | 8 | 2020 | 935 | 0.400 |
Why?
|
Comparative Effectiveness Research | 1 | 2012 | 130 | 0.390 |
Why?
|
Aortic Valve | 2 | 2021 | 400 | 0.390 |
Why?
|
Academic Medical Centers | 3 | 2020 | 413 | 0.380 |
Why?
|
Emotions | 7 | 2023 | 472 | 0.380 |
Why?
|
Social Environment | 1 | 2013 | 283 | 0.380 |
Why?
|
Cross-Sectional Studies | 9 | 2024 | 4409 | 0.380 |
Why?
|
Adaptation, Psychological | 7 | 2023 | 547 | 0.370 |
Why?
|
Sleep Apnea, Obstructive | 3 | 2020 | 200 | 0.370 |
Why?
|
Decision Support Systems, Clinical | 2 | 2023 | 176 | 0.370 |
Why?
|
Age Factors | 12 | 2020 | 2890 | 0.370 |
Why?
|
Myocarditis | 2 | 2022 | 93 | 0.370 |
Why?
|
Health Literacy | 4 | 2022 | 164 | 0.360 |
Why?
|
Income | 3 | 2020 | 167 | 0.360 |
Why?
|
Research Report | 5 | 2022 | 75 | 0.350 |
Why?
|
Patient Protection and Affordable Care Act | 3 | 2017 | 99 | 0.350 |
Why?
|
Risk | 4 | 2019 | 815 | 0.350 |
Why?
|
Communication | 5 | 2023 | 747 | 0.350 |
Why?
|
Erythrocyte Indices | 1 | 2009 | 28 | 0.350 |
Why?
|
Poverty | 1 | 2013 | 442 | 0.330 |
Why?
|
Cardiologists | 3 | 2018 | 40 | 0.330 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2021 | 486 | 0.330 |
Why?
|
Sex Factors | 7 | 2021 | 1717 | 0.330 |
Why?
|
Consensus | 6 | 2022 | 535 | 0.330 |
Why?
|
Hemodynamics | 5 | 2023 | 1013 | 0.320 |
Why?
|
Delivery of Health Care, Integrated | 3 | 2021 | 228 | 0.320 |
Why?
|
Weights and Measures | 1 | 2008 | 7 | 0.320 |
Why?
|
Eligibility Determination | 2 | 2021 | 60 | 0.310 |
Why?
|
Factor Xa Inhibitors | 2 | 2020 | 138 | 0.310 |
Why?
|
Liver Function Tests | 1 | 2009 | 103 | 0.310 |
Why?
|
Pain | 2 | 2018 | 710 | 0.310 |
Why?
|
Surgical Wound Infection | 1 | 2011 | 248 | 0.310 |
Why?
|
Anemia | 1 | 2009 | 144 | 0.310 |
Why?
|
Administration, Oral | 9 | 2021 | 731 | 0.310 |
Why?
|
Research Design | 5 | 2023 | 931 | 0.310 |
Why?
|
Internationality | 1 | 2008 | 144 | 0.290 |
Why?
|
Mitral Valve Insufficiency | 1 | 2008 | 63 | 0.290 |
Why?
|
Multivariate Analysis | 7 | 2013 | 1435 | 0.290 |
Why?
|
Erythrocytes | 2 | 2009 | 591 | 0.290 |
Why?
|
Incidence | 10 | 2018 | 2312 | 0.290 |
Why?
|
Mitral Valve | 1 | 2008 | 87 | 0.290 |
Why?
|
Cardiac Resynchronization Therapy | 2 | 2022 | 42 | 0.290 |
Why?
|
Betacoronavirus | 2 | 2020 | 252 | 0.280 |
Why?
|
Acute Kidney Injury | 1 | 2013 | 637 | 0.280 |
Why?
|
Referral and Consultation | 5 | 2023 | 632 | 0.280 |
Why?
|
Models, Cardiovascular | 1 | 2008 | 178 | 0.280 |
Why?
|
Breast Neoplasms | 3 | 2023 | 1868 | 0.280 |
Why?
|
Hospitals, Community | 2 | 2020 | 45 | 0.280 |
Why?
|
Prosthesis Design | 4 | 2018 | 285 | 0.270 |
Why?
|
Patient Care | 2 | 2023 | 103 | 0.270 |
Why?
|
Choice Behavior | 2 | 2020 | 154 | 0.270 |
Why?
|
Pilot Projects | 6 | 2022 | 1370 | 0.260 |
Why?
|
Patient Satisfaction | 4 | 2020 | 583 | 0.260 |
Why?
|
Evidence-Based Medicine | 4 | 2021 | 667 | 0.260 |
Why?
|
Cost-Benefit Analysis | 4 | 2021 | 545 | 0.260 |
Why?
|
Frailty | 2 | 2019 | 114 | 0.260 |
Why?
|
Cost of Illness | 5 | 2020 | 254 | 0.260 |
Why?
|
Mass Screening | 2 | 2010 | 1003 | 0.260 |
Why?
|
Prosthesis Implantation | 2 | 2019 | 139 | 0.250 |
Why?
|
Prevalence | 9 | 2020 | 2249 | 0.250 |
Why?
|
Patient Compliance | 4 | 2019 | 525 | 0.250 |
Why?
|
Patient Acceptance of Health Care | 4 | 2020 | 680 | 0.250 |
Why?
|
Marijuana Smoking | 2 | 2020 | 224 | 0.240 |
Why?
|
Mortality | 4 | 2020 | 288 | 0.240 |
Why?
|
Electric Countershock | 3 | 2020 | 104 | 0.240 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 815 | 0.240 |
Why?
|
Neoplasms | 3 | 2023 | 2105 | 0.240 |
Why?
|
Digital Divide | 1 | 2024 | 3 | 0.230 |
Why?
|
Depression | 4 | 2020 | 1133 | 0.230 |
Why?
|
Mobile Applications | 2 | 2024 | 140 | 0.230 |
Why?
|
Creatinine | 3 | 2023 | 424 | 0.230 |
Why?
|
Infusions, Intravenous | 3 | 2018 | 372 | 0.220 |
Why?
|
Reproducibility of Results | 5 | 2023 | 2763 | 0.220 |
Why?
|
Congresses as Topic | 3 | 2021 | 196 | 0.220 |
Why?
|
Clinical Coding | 2 | 2014 | 19 | 0.220 |
Why?
|
Chest Pain | 1 | 2023 | 80 | 0.220 |
Why?
|
Probability | 3 | 2016 | 291 | 0.220 |
Why?
|
Urea | 1 | 2023 | 68 | 0.220 |
Why?
|
Perinatal Care | 1 | 2023 | 36 | 0.220 |
Why?
|
Isosorbide Dinitrate | 1 | 2023 | 3 | 0.210 |
Why?
|
Hydralazine | 1 | 2023 | 5 | 0.210 |
Why?
|
Troponin | 1 | 2023 | 44 | 0.210 |
Why?
|
Denmark | 1 | 2023 | 39 | 0.210 |
Why?
|
Drug Utilization | 2 | 2015 | 167 | 0.210 |
Why?
|
Cardiac Rehabilitation | 1 | 2023 | 33 | 0.210 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2022 | 2097 | 0.210 |
Why?
|
Recovery of Function | 4 | 2020 | 572 | 0.210 |
Why?
|
Death | 1 | 2023 | 107 | 0.210 |
Why?
|
Pulmonary Artery | 1 | 2008 | 1012 | 0.210 |
Why?
|
Atrial Appendage | 1 | 2022 | 10 | 0.200 |
Why?
|
Pandemics | 2 | 2020 | 1319 | 0.200 |
Why?
|
Patient Care Bundles | 1 | 2021 | 17 | 0.200 |
Why?
|
Cognition | 4 | 2021 | 989 | 0.190 |
Why?
|
Anxiety | 3 | 2018 | 842 | 0.190 |
Why?
|
Advisory Committees | 2 | 2021 | 208 | 0.190 |
Why?
|
Electrophysiologic Techniques, Cardiac | 1 | 2021 | 70 | 0.190 |
Why?
|
Hypertension | 3 | 2021 | 1059 | 0.190 |
Why?
|
Universities | 1 | 2023 | 339 | 0.190 |
Why?
|
Trust | 1 | 2022 | 105 | 0.190 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2021 | 88 | 0.190 |
Why?
|
Age Distribution | 3 | 2012 | 339 | 0.180 |
Why?
|
Myocardial Contraction | 2 | 2019 | 312 | 0.180 |
Why?
|
Relaxin | 1 | 2020 | 15 | 0.180 |
Why?
|
Georgia | 1 | 2020 | 62 | 0.180 |
Why?
|
Norway | 1 | 2020 | 36 | 0.180 |
Why?
|
Health Systems Plans | 1 | 2020 | 3 | 0.180 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2020 | 400 | 0.180 |
Why?
|
Psychology | 1 | 2021 | 81 | 0.180 |
Why?
|
Financing, Government | 1 | 2020 | 40 | 0.180 |
Why?
|
Home Care Services | 2 | 2020 | 222 | 0.180 |
Why?
|
Palliative Medicine | 2 | 2018 | 14 | 0.180 |
Why?
|
Pyridones | 1 | 2021 | 123 | 0.180 |
Why?
|
Health Services Misuse | 1 | 2020 | 36 | 0.180 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2020 | 106 | 0.170 |
Why?
|
Diagnosis-Related Groups | 2 | 2021 | 27 | 0.170 |
Why?
|
Health Resources | 2 | 2012 | 122 | 0.170 |
Why?
|
Odds Ratio | 5 | 2014 | 954 | 0.170 |
Why?
|
Thoracentesis | 1 | 2019 | 8 | 0.170 |
Why?
|
Nurses | 3 | 2018 | 145 | 0.170 |
Why?
|
Tertiary Care Centers | 1 | 2020 | 126 | 0.170 |
Why?
|
Mandatory Programs | 1 | 2019 | 15 | 0.170 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 168 | 0.170 |
Why?
|
Minimal Clinically Important Difference | 1 | 2019 | 10 | 0.170 |
Why?
|
Dyspnea | 3 | 2018 | 213 | 0.160 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2022 | 240 | 0.160 |
Why?
|
Multicenter Studies as Topic | 1 | 2020 | 249 | 0.160 |
Why?
|
Fatigue | 3 | 2018 | 295 | 0.160 |
Why?
|
Mental Competency | 1 | 2019 | 26 | 0.160 |
Why?
|
Atherosclerosis | 1 | 2022 | 342 | 0.160 |
Why?
|
Coronary Artery Disease | 3 | 2019 | 607 | 0.160 |
Why?
|
Text Messaging | 1 | 2021 | 154 | 0.160 |
Why?
|
Home Infusion Therapy | 1 | 2018 | 4 | 0.160 |
Why?
|
Guidelines as Topic | 2 | 2017 | 244 | 0.160 |
Why?
|
Social Determinants of Health | 1 | 2020 | 135 | 0.160 |
Why?
|
Fee-for-Service Plans | 2 | 2018 | 83 | 0.160 |
Why?
|
Medical Marijuana | 1 | 2020 | 97 | 0.160 |
Why?
|
Contraindications | 2 | 2015 | 85 | 0.150 |
Why?
|
Thromboembolism | 2 | 2021 | 93 | 0.150 |
Why?
|
Patient Safety | 3 | 2021 | 278 | 0.150 |
Why?
|
Ventricular Function | 1 | 2018 | 56 | 0.150 |
Why?
|
Attitude of Health Personnel | 3 | 2020 | 977 | 0.150 |
Why?
|
Heart Failure, Diastolic | 1 | 2018 | 20 | 0.150 |
Why?
|
Reimbursement Mechanisms | 1 | 2018 | 77 | 0.150 |
Why?
|
Drug Administration Schedule | 3 | 2020 | 718 | 0.150 |
Why?
|
Cost Savings | 2 | 2021 | 74 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2014 | 1846 | 0.150 |
Why?
|
Heart Conduction System | 1 | 2018 | 82 | 0.150 |
Why?
|
Spouses | 1 | 2018 | 85 | 0.150 |
Why?
|
Mental Health | 1 | 2023 | 560 | 0.150 |
Why?
|
Thrombosis | 1 | 2021 | 297 | 0.150 |
Why?
|
Medical Records | 1 | 2018 | 153 | 0.140 |
Why?
|
Quality Control | 1 | 2017 | 144 | 0.140 |
Why?
|
Spiritual Therapies | 1 | 2017 | 9 | 0.140 |
Why?
|
Vaccines | 1 | 2022 | 375 | 0.140 |
Why?
|
Nervous System Diseases | 1 | 2020 | 252 | 0.140 |
Why?
|
Blood Coagulation | 1 | 2018 | 217 | 0.140 |
Why?
|
Caliciviridae Infections | 1 | 2016 | 17 | 0.140 |
Why?
|
Drug Therapy, Combination | 2 | 2019 | 954 | 0.140 |
Why?
|
Pain Management | 2 | 2016 | 289 | 0.140 |
Why?
|
Databases, Factual | 2 | 2012 | 1128 | 0.130 |
Why?
|
Mexiletine | 1 | 2016 | 7 | 0.130 |
Why?
|
Amphetamine | 1 | 2016 | 22 | 0.130 |
Why?
|
Predictive Value of Tests | 4 | 2021 | 1796 | 0.130 |
Why?
|
Defibrillators | 1 | 2016 | 16 | 0.130 |
Why?
|
Thrombolytic Therapy | 1 | 2017 | 117 | 0.130 |
Why?
|
Truth Disclosure | 1 | 2016 | 39 | 0.130 |
Why?
|
Public Health | 1 | 2020 | 434 | 0.130 |
Why?
|
Emergency Service, Hospital | 2 | 2023 | 1812 | 0.130 |
Why?
|
Bereavement | 1 | 2016 | 49 | 0.130 |
Why?
|
Substance Abuse Detection | 1 | 2016 | 62 | 0.130 |
Why?
|
Antihypertensive Agents | 2 | 2023 | 429 | 0.130 |
Why?
|
Uncertainty | 1 | 2016 | 96 | 0.130 |
Why?
|
Psychotherapy | 1 | 2017 | 149 | 0.130 |
Why?
|
Social Security | 1 | 2015 | 4 | 0.130 |
Why?
|
Medical Indigency | 1 | 2015 | 11 | 0.130 |
Why?
|
Kidney | 2 | 2020 | 1184 | 0.120 |
Why?
|
Waiting Lists | 1 | 2017 | 211 | 0.120 |
Why?
|
Transplant Recipients | 1 | 2016 | 140 | 0.120 |
Why?
|
Young Adult | 7 | 2019 | 10463 | 0.120 |
Why?
|
Self Care | 2 | 2019 | 350 | 0.120 |
Why?
|
Drug Monitoring | 1 | 2016 | 184 | 0.120 |
Why?
|
Information Seeking Behavior | 1 | 2015 | 35 | 0.120 |
Why?
|
Polypharmacy | 1 | 2015 | 74 | 0.120 |
Why?
|
Glycogen Storage Disease Type IIb | 1 | 2014 | 22 | 0.120 |
Why?
|
Cognitive Dysfunction | 1 | 2019 | 284 | 0.120 |
Why?
|
Assisted Circulation | 1 | 2014 | 25 | 0.120 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2015 | 51 | 0.120 |
Why?
|
Health Surveys | 3 | 2023 | 443 | 0.120 |
Why?
|
Drug Hypersensitivity | 1 | 2015 | 85 | 0.120 |
Why?
|
Patient Outcome Assessment | 1 | 2015 | 121 | 0.110 |
Why?
|
Critical Care | 1 | 2018 | 473 | 0.110 |
Why?
|
Cobalt | 1 | 2014 | 46 | 0.110 |
Why?
|
Cooperative Behavior | 1 | 2016 | 381 | 0.110 |
Why?
|
Calcium | 1 | 2019 | 1103 | 0.110 |
Why?
|
Potassium | 1 | 2013 | 128 | 0.110 |
Why?
|
Peripheral Arterial Disease | 1 | 2019 | 380 | 0.110 |
Why?
|
Women's Health | 1 | 2015 | 271 | 0.110 |
Why?
|
Data Collection | 1 | 2016 | 622 | 0.110 |
Why?
|
Infant, Newborn | 1 | 2023 | 5035 | 0.100 |
Why?
|
Antineoplastic Agents | 2 | 2014 | 1895 | 0.100 |
Why?
|
Anthracyclines | 1 | 2012 | 41 | 0.100 |
Why?
|
Geriatric Assessment | 1 | 2013 | 176 | 0.100 |
Why?
|
Health Maintenance Organizations | 1 | 2012 | 93 | 0.100 |
Why?
|
Drug Utilization Review | 1 | 2012 | 57 | 0.100 |
Why?
|
Body Mass Index | 2 | 2019 | 1958 | 0.100 |
Why?
|
Patients | 2 | 2024 | 162 | 0.100 |
Why?
|
Sickness Impact Profile | 1 | 2011 | 50 | 0.100 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 248 | 0.100 |
Why?
|
Pregnancy | 1 | 2023 | 5525 | 0.100 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 904 | 0.100 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2012 | 48 | 0.100 |
Why?
|
Acculturation | 1 | 2012 | 50 | 0.100 |
Why?
|
Tachycardia | 1 | 2011 | 50 | 0.090 |
Why?
|
Echocardiography | 1 | 2014 | 554 | 0.090 |
Why?
|
Myocardial Ischemia | 1 | 2012 | 234 | 0.090 |
Why?
|
Hyponatremia | 1 | 2011 | 37 | 0.090 |
Why?
|
Culture | 1 | 2012 | 124 | 0.090 |
Why?
|
Lung Diseases | 1 | 2017 | 696 | 0.090 |
Why?
|
Motivation | 1 | 2015 | 494 | 0.090 |
Why?
|
Cognition Disorders | 1 | 2015 | 477 | 0.090 |
Why?
|
Glomerular Filtration Rate | 2 | 2013 | 604 | 0.090 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 916 | 0.090 |
Why?
|
Logistic Models | 2 | 2013 | 1843 | 0.090 |
Why?
|
Antidiuretic Hormone Receptor Antagonists | 1 | 2010 | 8 | 0.090 |
Why?
|
Health Services Research | 1 | 2013 | 371 | 0.090 |
Why?
|
Minority Groups | 1 | 2012 | 227 | 0.090 |
Why?
|
Erythropoiesis | 1 | 2009 | 34 | 0.090 |
Why?
|
Confidence Intervals | 3 | 2020 | 309 | 0.090 |
Why?
|
Benzazepines | 1 | 2010 | 37 | 0.090 |
Why?
|
Injections, Intravenous | 1 | 2010 | 201 | 0.090 |
Why?
|
Focus Groups | 2 | 2023 | 385 | 0.080 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 1340 | 0.080 |
Why?
|
Electric Stimulation Therapy | 1 | 2010 | 56 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 373 | 0.080 |
Why?
|
Endpoint Determination | 1 | 2009 | 69 | 0.080 |
Why?
|
Residence Characteristics | 1 | 2011 | 275 | 0.080 |
Why?
|
ROC Curve | 1 | 2010 | 445 | 0.080 |
Why?
|
Bilirubin | 1 | 2009 | 88 | 0.080 |
Why?
|
Aspartate Aminotransferases | 1 | 2009 | 86 | 0.080 |
Why?
|
Alberta | 1 | 2008 | 10 | 0.080 |
Why?
|
Actuarial Analysis | 1 | 2008 | 21 | 0.080 |
Why?
|
Data Interpretation, Statistical | 1 | 2010 | 322 | 0.080 |
Why?
|
United States Food and Drug Administration | 1 | 2009 | 172 | 0.080 |
Why?
|
Syndrome | 1 | 2009 | 334 | 0.080 |
Why?
|
Lung Neoplasms | 2 | 2023 | 2199 | 0.080 |
Why?
|
Alanine Transaminase | 1 | 2009 | 141 | 0.080 |
Why?
|
Alkaline Phosphatase | 1 | 2009 | 143 | 0.080 |
Why?
|
Serum Albumin | 1 | 2009 | 134 | 0.080 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2012 | 664 | 0.080 |
Why?
|
Substance-Related Disorders | 1 | 2016 | 947 | 0.070 |
Why?
|
Social Support | 3 | 2019 | 528 | 0.070 |
Why?
|
DNA | 1 | 2014 | 1351 | 0.070 |
Why?
|
Insurance Coverage | 2 | 2021 | 201 | 0.070 |
Why?
|
Child | 2 | 2023 | 18352 | 0.070 |
Why?
|
Social Workers | 2 | 2018 | 32 | 0.070 |
Why?
|
Ultrafiltration | 1 | 2007 | 27 | 0.070 |
Why?
|
Heart Function Tests | 1 | 2007 | 58 | 0.070 |
Why?
|
Benzimidazoles | 1 | 2007 | 138 | 0.070 |
Why?
|
Liver Diseases | 1 | 2009 | 254 | 0.070 |
Why?
|
Lung | 1 | 2018 | 3546 | 0.060 |
Why?
|
Genomics | 1 | 2010 | 639 | 0.060 |
Why?
|
Feasibility Studies | 2 | 2020 | 737 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2011 | 763 | 0.060 |
Why?
|
Vasodilator Agents | 1 | 2007 | 303 | 0.060 |
Why?
|
Proteomics | 1 | 2010 | 843 | 0.060 |
Why?
|
Diabetes Complications | 1 | 2006 | 211 | 0.060 |
Why?
|
Natriuretic Peptides | 1 | 2023 | 8 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2007 | 1122 | 0.060 |
Why?
|
Cardiac Surgical Procedures | 1 | 2008 | 413 | 0.060 |
Why?
|
Critical Illness | 1 | 2008 | 643 | 0.060 |
Why?
|
Prescriptions | 1 | 2023 | 60 | 0.050 |
Why?
|
Cardiac Output | 1 | 2023 | 142 | 0.050 |
Why?
|
Renin-Angiotensin System | 1 | 2023 | 71 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 3039 | 0.050 |
Why?
|
Heuristics | 1 | 2022 | 8 | 0.050 |
Why?
|
Information Systems | 1 | 2023 | 61 | 0.050 |
Why?
|
Sexism | 1 | 2023 | 44 | 0.050 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 12 | 0.050 |
Why?
|
Multimorbidity | 1 | 2022 | 34 | 0.050 |
Why?
|
Massachusetts | 1 | 2022 | 134 | 0.050 |
Why?
|
Phenotype | 2 | 2021 | 2812 | 0.050 |
Why?
|
Artificial Intelligence | 1 | 2023 | 145 | 0.050 |
Why?
|
Sodium | 1 | 2022 | 182 | 0.050 |
Why?
|
Program Development | 1 | 2023 | 342 | 0.050 |
Why?
|
Return to Sport | 1 | 2022 | 80 | 0.050 |
Why?
|
Critical Pathways | 1 | 2022 | 74 | 0.050 |
Why?
|
Policy | 1 | 2022 | 137 | 0.050 |
Why?
|
Exercise Test | 1 | 2023 | 544 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 299 | 0.040 |
Why?
|
Attitude | 1 | 2022 | 229 | 0.040 |
Why?
|
Urban Health Services | 1 | 2020 | 60 | 0.040 |
Why?
|
International Classification of Diseases | 1 | 2021 | 117 | 0.040 |
Why?
|
Organizations, Nonprofit | 1 | 2020 | 17 | 0.040 |
Why?
|
Private Sector | 1 | 2020 | 51 | 0.040 |
Why?
|
Rural Health Services | 1 | 2020 | 93 | 0.040 |
Why?
|
Intracranial Embolism | 1 | 2019 | 29 | 0.040 |
Why?
|
Stakeholder Participation | 1 | 2020 | 73 | 0.040 |
Why?
|
Public Opinion | 1 | 2020 | 59 | 0.040 |
Why?
|
Embolism | 1 | 2019 | 43 | 0.040 |
Why?
|
Contraindications, Procedure | 1 | 2019 | 11 | 0.040 |
Why?
|
Canada | 1 | 2020 | 322 | 0.040 |
Why?
|
Visual Analog Scale | 1 | 2019 | 31 | 0.040 |
Why?
|
Disease Susceptibility | 1 | 2021 | 316 | 0.040 |
Why?
|
Myocardial Revascularization | 1 | 2019 | 67 | 0.040 |
Why?
|
Hyperlipidemias | 1 | 2019 | 122 | 0.040 |
Why?
|
Peripheral Vascular Diseases | 1 | 2019 | 97 | 0.040 |
Why?
|
Sex Characteristics | 1 | 2023 | 640 | 0.040 |
Why?
|
Observational Studies as Topic | 1 | 2019 | 90 | 0.040 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 121 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 101 | 0.040 |
Why?
|
Government Regulation | 1 | 2018 | 46 | 0.040 |
Why?
|
Survival | 1 | 2018 | 37 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2017 | 1691 | 0.040 |
Why?
|
Treatment Failure | 1 | 2019 | 332 | 0.040 |
Why?
|
Walk Test | 1 | 2018 | 52 | 0.040 |
Why?
|
Hospitals, Rural | 1 | 2018 | 31 | 0.040 |
Why?
|
Patient Health Questionnaire | 1 | 2018 | 20 | 0.040 |
Why?
|
Policy Making | 1 | 2018 | 81 | 0.040 |
Why?
|
Drug Dosage Calculations | 1 | 2018 | 21 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2022 | 668 | 0.040 |
Why?
|
Exercise Tolerance | 1 | 2019 | 213 | 0.040 |
Why?
|
Medicare Part D | 1 | 2018 | 26 | 0.040 |
Why?
|
Hospitals, Urban | 1 | 2018 | 127 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2016 | 2386 | 0.040 |
Why?
|
Random Allocation | 1 | 2018 | 335 | 0.040 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 201 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2020 | 1233 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2018 | 258 | 0.040 |
Why?
|
Glucose | 1 | 2022 | 897 | 0.040 |
Why?
|
Risk Management | 1 | 2018 | 89 | 0.040 |
Why?
|
Diphenoxylate | 1 | 2016 | 5 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 621 | 0.030 |
Why?
|
Atropine | 1 | 2016 | 25 | 0.030 |
Why?
|
Loperamide | 1 | 2016 | 10 | 0.030 |
Why?
|
Antidiarrheals | 1 | 2016 | 15 | 0.030 |
Why?
|
Propensity Score | 1 | 2018 | 224 | 0.030 |
Why?
|
Emotional Adjustment | 1 | 2016 | 17 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2016 | 36 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2023 | 925 | 0.030 |
Why?
|
Voltage-Gated Sodium Channel Blockers | 1 | 2016 | 5 | 0.030 |
Why?
|
Chromatography, Gas | 1 | 2016 | 27 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2018 | 460 | 0.030 |
Why?
|
Gastrointestinal Agents | 1 | 2016 | 60 | 0.030 |
Why?
|
Postoperative Period | 1 | 2017 | 289 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2017 | 122 | 0.030 |
Why?
|
Data Accuracy | 1 | 2016 | 48 | 0.030 |
Why?
|
Symptom Assessment | 1 | 2016 | 119 | 0.030 |
Why?
|
Video Recording | 1 | 2016 | 142 | 0.030 |
Why?
|
Life Change Events | 1 | 2016 | 135 | 0.030 |
Why?
|
Physicians, Primary Care | 1 | 2018 | 222 | 0.030 |
Why?
|
Lysosomal-Associated Membrane Protein 2 | 1 | 2014 | 26 | 0.030 |
Why?
|
Central Nervous System Stimulants | 1 | 2016 | 139 | 0.030 |
Why?
|
Reference Values | 1 | 2016 | 742 | 0.030 |
Why?
|
Linear Models | 1 | 2017 | 770 | 0.030 |
Why?
|
Family Relations | 1 | 2015 | 85 | 0.030 |
Why?
|
Treatment Refusal | 1 | 2015 | 85 | 0.030 |
Why?
|
Intensive Care Units | 1 | 2018 | 618 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2016 | 994 | 0.030 |
Why?
|
Morbidity | 1 | 2014 | 277 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 372 | 0.030 |
Why?
|
Proteinuria | 1 | 2013 | 77 | 0.030 |
Why?
|
Hospitals, Veterans | 1 | 2014 | 244 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 513 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 647 | 0.030 |
Why?
|
Systole | 1 | 2013 | 171 | 0.030 |
Why?
|
Trastuzumab | 1 | 2012 | 89 | 0.030 |
Why?
|
Global Health | 1 | 2014 | 288 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 494 | 0.020 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2012 | 109 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2019 | 1009 | 0.020 |
Why?
|
Precision Medicine | 1 | 2015 | 338 | 0.020 |
Why?
|
Evidence-Based Practice | 1 | 2013 | 185 | 0.020 |
Why?
|
Forecasting | 1 | 2013 | 331 | 0.020 |
Why?
|
History, 21st Century | 1 | 2012 | 160 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2012 | 333 | 0.020 |
Why?
|
History, 20th Century | 1 | 2012 | 265 | 0.020 |
Why?
|
Medical Audit | 1 | 2011 | 75 | 0.020 |
Why?
|
Managed Care Programs | 1 | 2011 | 133 | 0.020 |
Why?
|
Needs Assessment | 1 | 2011 | 313 | 0.020 |
Why?
|
Social Class | 1 | 2011 | 204 | 0.020 |
Why?
|
Hypertension, Pulmonary | 1 | 2019 | 1728 | 0.020 |
Why?
|
Health Care Rationing | 1 | 2008 | 45 | 0.020 |
Why?
|
Databases as Topic | 1 | 2007 | 63 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 2269 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 2099 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1361 | 0.010 |
Why?
|
Mutation | 1 | 2014 | 3350 | 0.010 |
Why?
|
Adolescent | 1 | 2017 | 17808 | 0.010 |
Why?
|
Animals | 1 | 2012 | 31762 | 0.010 |
Why?
|